NASDAQ : VERA
Vera Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 30.53 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.20B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 153.89M | 100.22M | 41.00M | 23.79M | 21.91M | 11.92M |
| Research & Development | 261.87M | 215.26M | 126.17M | 78.22M | 68.99M | 22.48M |
| Operating Expenses | 415.76M | 315.47M | 167.17M | 102.01M | 90.90M | 34.40M |
| Operating Income | -415.76M | -315.47M | -167.17M | -102.01M | -90.90M | -34.40M |
| Interest Expense | -7.54M | -7.53M | -7.63M | -3.79M | -992.00K | -20.00K |
| Interest & Investment Income | 22.96M | 24.48M | 20.71M | 7.98M | 1.75M | 15.00K |
| Other Non Operating Income (Expenses) | -555.00K | -89.00K | 1.94M | 1.83M | 1.90M | |
| EBT Excluding Unusual Items | -400.89M | -298.61M | -152.15M | -95.99M | -88.25M | -34.41M |
| Gain (Loss) on Sale of Investments | -809.00K | -892.00K | ||||
| Gain (Loss) on Sale of Assets | 2.69M | |||||
| Other Unusual Items | -1.00M | -1.00M | ||||
| Pretax Income | -401.89M | -299.61M | -152.15M | -95.99M | -89.06M | -32.61M |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -401.89M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
| Net Income to Common | -401.89M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
| Shares Outstanding (Basic) | 68.20M | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M |
| Shares Outstanding (Diluted) | 68.20M | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M |
| EPS (Basic) | -5.89 | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 |
| EPS (Diluted) | -5.89 | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 |
| Free Cash Flow | -338.91M | -241.73M | -135.65M | -92.24M | -67.66M | -23.71M |
| Free Cash Flow Per Share | -4.97 | -3.76 | -2.45 | -2.16 | -2.55 | -1.76 |
| EBITDA | -415.22M | -315.00M | -167.06M | -101.99M | -90.73M | -34.23M |
| D&A For EBITDA | 536.00K | 468.00K | 105.00K | 21.00K | 176.00K | 176.00K |
| EBIT | -415.76M | -315.47M | -167.17M | -102.01M | -90.90M | -34.40M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 48.88M | 354.73M | 92.65M | 45.68M | 43.46M | 79.67M |
| Short-Term Investments | 450.29M | 359.86M | 548.21M | 115.03M | 71.19M | |
| Cash & Short-Term Investments | 499.16M | 714.59M | 640.85M | 160.72M | 114.65M | 79.67M |
| Other Receivables | 3.93M | 3.29M | 3.77M | 512.00K | ||
| Receivables | 3.93M | 3.29M | 3.77M | 512.00K | ||
| Prepaid Expenses | 20.20M | 8.47M | 5.21M | 8.56M | 10.33M | 2.38M |
| Other Current Assets | 4.21M | 2.54M | 1.38M | 2.24M | 719.00K | 480.00K |
| Total Current Assets | 527.49M | 728.88M | 651.22M | 172.02M | 125.70M | 82.54M |
| Property, Plant & Equipment | 2.50M | 3.30M | 4.33M | 3.04M | 5.22M | |
| Long-Term Investments | 58.00K | 867.00K | ||||
| Other Long-Term Assets | 613.00K | 2.55M | 131.00K | 482.00K | 455.00K | 344.00K |
| Total Assets | 532.98M | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M |
| Accounts Payable | 14.57M | 21.90M | 7.67M | 11.12M | 11.99M | 1.39M |
| Accrued Expenses | 31.02M | 29.64M | 14.47M | 8.75M | 10.96M | 5.93M |
| Current Portion of Leases | 549.00K | 1.48M | 2.44M | 2.65M | ||
| Other Current Liabilities | 2.73M | 1.37M | 1.75M | 377.00K | ||
| Total Current Liabilities | 48.32M | 53.45M | 25.37M | 22.30M | 25.60M | 7.69M |
| Long-Term Debt | 75.23M | 74.84M | 50.69M | 49.88M | 24.81M | 4.92M |
| Long-Term Leases | 1.68M | 1.92M | 2.47M | 1.40M | 3.83M | |
| Other Long-Term Liabilities | 286.00K | 286.00K | 1.54M | |||
| Total Liabilities | 125.23M | 130.21M | 78.53M | 73.86M | 54.53M | 14.16M |
| Common Stock | 72.00K | 71.00K | 64.00K | 44.00K | 28.00K | 21.00K |
| Additional Paid-In Capital | 1.40B | 1.36B | 1.04B | 410.49M | 290.22M | 193.63M |
| Retained Earnings | -991.37M | -760.87M | -461.25M | -309.10M | -213.11M | -124.06M |
| Comprehensive Income & Other | -403.00K | 786.00K | 393.00K | 251.00K | -224.00K | |
| Total Common Equity | 407.76M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
| Shareholders' Equity | 407.76M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
| Total Liabilities & Equity | 532.98M | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M |
| Total Debt | 76.91M | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M |
| Net Cash (Debt) | 422.26M | 637.28M | 586.21M | 107.01M | 83.37M | 74.75M |
| Net Cash Per Share | 6.19 | 9.92 | 10.60 | 2.51 | 3.14 | 5.56 |
| Filing Date Shares Outstanding | 72.06M | 71.36M | 63.75M | 54.45M | 44.26M | 27.05M |
| Total Common Shares Outstanding | 71.96M | 71.27M | 63.56M | 44.45M | 27.80M | 21.28M |
| Working Capital | 479.17M | 675.43M | 625.85M | 149.72M | 100.10M | 74.85M |
| Book Value Per Share | 5.67 | 8.48 | 9.08 | 2.29 | 2.77 | 3.27 |
| Tangible Book Value | 406.96M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
| Tangible Book Value Per Share | 5.66 | 8.48 | 9.08 | 2.29 | 2.77 | 3.27 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -401.89M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
| Depreciation & Amortization | 536.00K | 468.00K | 105.00K | 21.00K | -846.00K | 176.00K |
| Loss (Gain) From Sale of Assets | -2.69M | |||||
| Asset Writedown & Restructuring Costs | -999.00K | |||||
| Loss (Gain) From Sale of Investments | -4.50M | -6.98M | -8.97M | -4.43M | 809.00K | 892.00K |
| Stock-Based Compensation | 49.78M | 37.93M | 20.80M | 11.49M | 8.89M | 3.01M |
| Other Operating Activities | 18.55M | 4.11M | 2.87M | 2.55M | 5.86M | 5.00M |
| Change in Accounts Payable | 1.12M | 13.91M | -3.45M | -873.00K | 10.61M | 475.00K |
| Change in Other Net Operating Assets | -2.24M | 9.08M | 6.11M | -4.95M | -3.86M | 3.04M |
| Operating Cash Flow | -338.65M | -241.10M | -134.68M | -92.18M | -67.60M | -23.71M |
| Capital Expenditures | -258.00K | -630.00K | -972.00K | -63.00K | -62.00K | |
| Sale of Property, Plant & Equipment | 796.00K | |||||
| Sale (Purchase) of Intangibles | -264.00K | -5.00M | ||||
| Investment in Securities | 60.99M | 195.72M | -424.06M | -39.37M | -70.49M | |
| Other Investing Activities | -15.00M | -800.00K | ||||
| Investing Cash Flow | 45.47M | 194.29M | -425.03M | -39.43M | -70.55M | -4.20M |
| Long-Term Debt Issued | 23.34M | 24.74M | 19.82M | 4.92M | ||
| Total Debt Issued | 23.34M | 24.74M | 19.82M | 4.92M | ||
| Net Debt Issued (Repaid) | 23.34M | 24.74M | 19.82M | 4.92M | ||
| Issuance of Common Stock | 310.84M | 306.98M | 645.91M | 116.06M | 88.21M | 51.73M |
| Repurchase of Common Stock | -13.00K | |||||
| Other Financing Activities | -17.91M | -21.42M | -39.23M | -7.26M | -6.10M | -2.77M |
| Financing Cash Flow | 292.94M | 308.90M | 606.67M | 133.54M | 101.93M | 53.88M |
| Net Cash Flow | -245.00K | 262.08M | 46.97M | 1.93M | -36.22M | 25.97M |
| Free Cash Flow | -338.91M | -241.73M | -135.65M | -92.24M | -67.66M | -23.71M |
| Free Cash Flow Per Share | -4.97 | -3.76 | -2.45 | -2.16 | -2.55 | -1.76 |
| Levered Free Cash Flow | -212.95M | -139.02M | -84.35M | -58.02M | -42.37M | -20.38M |
| Unlevered Free Cash Flow | -208.24M | -134.32M | -79.58M | -55.66M | -41.75M | -20.37M |
| Cash Interest Paid | 6.76M | 6.72M | 6.65M | 3.35M | 895.00K | 17.00K |
| Change in Working Capital | -1.12M | 22.99M | 2.66M | -5.82M | 6.75M | 3.51M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 2.18B | 3.59B | 2.68B | 683.38M | 535.18M | 568.54M |
| Enterprise Value | 1.76B | 3.17B | 2.38B | 552.96M | 432.89M | 482.29M |
| Last Close Price | 30.25 | 50.64 | 42.29 | 15.38 | 19.35 | 26.72 |
| PB Ratio | 5.34 | 5.95 | 4.64 | 6.72 | 6.96 | 8.17 |
| P/TBV Ratio | 5.36 | 5.95 | 4.64 | 6.72 | 6.96 | 8.17 |
| Debt / Equity Ratio | 0.19 | 0.13 | 0.10 | 0.53 | 0.41 | 0.07 |
| Net Debt / Equity Ratio | -1.04 | -1.05 | -1.02 | -1.05 | -1.08 | -1.07 |
| Net Debt / EBITDA Ratio | 1.02 | 2.02 | 3.51 | 1.05 | 0.92 | 2.18 |
| Net Debt / FCF Ratio | 1.25 | 2.64 | 4.32 | 1.16 | 1.23 | 3.15 |
| Quick Ratio | 10.41 | 13.43 | 25.41 | 7.23 | 4.48 | 10.36 |
| Current Ratio | 10.92 | 13.63 | 25.67 | 7.71 | 4.91 | 10.73 |
| Return on Equity (ROE) | -91.75% | -50.71% | -44.83% | -107.50% | -121.58% | -54.43% |
| Return on Assets (ROA) | -46.76% | -28.36% | -25.14% | -41.54% | -52.81% | -31.09% |
| Return on Capital Employed (ROCE) | -85.80% | -46.30% | -26.50% | -66.60% | -85.90% | -45.20% |
| Earnings Yield | -19.48% | -8.33% | -5.68% | -14.05% | -16.64% | -5.74% |
| FCF Yield | -15.55% | -6.73% | -5.07% | -13.50% | -12.64% | -4.17% |
| Buyback Yield / Dilution | -12.23% | -16.10% | -29.55% | -60.73% | -97.76% | -4,099.14% |